Veru Reports Fiscal 2025 First Quarter Financial Results and Clinical Program Progress
Provided By GlobeNewswire
Last update: Feb 13, 2025
--Company reported positive Phase 2b QUALITY study topline results for enobosarm + semaglutide (Wegovy®) with study meeting prespecified primary endpoint of preservation of lean mass as well as greater fat loss and improvement of physical function--
Read more at globenewswire.comNASDAQ:VERU (4/21/2025, 3:44:01 PM)
0.5241
-0.01 (-1.89%)
Find more stocks in the Stock Screener
VERU Latest News and Analysis
20 days ago - ChartmillWhich stocks are experiencing notable movement on Tuesday?Let's have a look at what is happening on the US markets in the middle of the day on Tuesday. Below you can find the top gainers and losers in today's session.
20 days ago - ChartmillLet's uncover which stocks are experiencing notable gaps during today's session.There are notable gap-ups and gap-downs in today's session. Let's take a look at which stocks are gapping on Tuesday.
